PDCD1 and head and neck squamous cell carcinoma: Altogether, our study sheds light not only on anti-PD-1/PD-L1 resistance in cSCC, HNSCC, and melanoma patients but also on potential biomarkers to predict the response to this therapy and possible alternative treatments for these diseases.